A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium.

@article{Lam2004ARP,
  title={A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium.},
  author={Stephen C-T Lam and Jean C Leriche and Annette McWilliams and Calum MacAulay and Yulia Dyachkova and Eva Szabo and John Mayo and Robert S. Schellenberg and Andy Coldman and Ernest T. Hawk and Adi Gazdar},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2004},
  volume={10 19},
  pages={
          6502-11
        }
}
PURPOSE Preclinical studies suggest that inhaled budesonide may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of inhaled budesonide in smokers with bronchial dysplasia. EXPERIMENTAL DESIGN A total of 112 smokers with more than or equal to one site of bronchial dysplasia > 1.2 mm in size identified by autofluorescence bronchoscopy-directed biopsy was randomly assigned to receive placebo or budesonide (Pulmicort Turbuhaler) 800… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

A phase I study of myo-inositol for lung cancer chemoprevention.

  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2006
VIEW 5 EXCERPTS

The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial.

  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2006
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND